Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease

[1] Elsworth JD(1997)Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease Exp Neurol 144 4-9

[2] Roth RH(1985)Sequence and significance of dopamine metabolism in the rat brain Neurochem Int 7 221-227

[3] Westerink BH(1992)Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors Prog Drug Res 39 291-350

[4] Männistö PT(2003)Parkinson's disease: mechanisms and models Neuron 39 889-909

[5] Ulmanen I(2002)Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease Clin Pharmacokinet 41 261-309

[6] Lundström K(2004)The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits Neurology 62 S17-S30

[7] Taskinen J(2006)Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update Clin Pharmacokinet 45 109-136

[8] Tenhunen J(2008)Motor complications in Parkinson disease: clinical manifestations and management J Neurol Sci 266 204-215

[9] Tilgmann C(2008)Current status of symptomatic medical therapy in Parkinson's disease Neurotherapeutics 5 164-180

[10] Kaakkola S(2010)Structure and function of the blood-brain barrier Neurobiol Dis 37 13-25

[1] Elsworth JD(1997)Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease Exp Neurol 144 4-9

[2] Roth RH(1985)Sequence and significance of dopamine metabolism in the rat brain Neurochem Int 7 221-227

[3] Westerink BH(1992)Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors Prog Drug Res 39 291-350

[4] Männistö PT(2003)Parkinson's disease: mechanisms and models Neuron 39 889-909

[5] Ulmanen I(2002)Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease Clin Pharmacokinet 41 261-309

[6] Lundström K(2004)The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits Neurology 62 S17-S30

[7] Taskinen J(2006)Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update Clin Pharmacokinet 45 109-136

[8] Tenhunen J(2008)Motor complications in Parkinson disease: clinical manifestations and management J Neurol Sci 266 204-215

[9] Tilgmann C(2008)Current status of symptomatic medical therapy in Parkinson's disease Neurotherapeutics 5 164-180

[10] Kaakkola S(2010)Structure and function of the blood-brain barrier Neurobiol Dis 37 13-25